论文部分内容阅读
全球第一大制剂生产国、第二大原料合成国家、仿制药大国,这是世界医药业界给中国的定位。这看上去很美的光环背后,却是中国医药市场上县级以上三家医院60%的产品由跨国药企提供,65%的利润为跨国企业所有的尴尬局面。“这就意味着国内近4000家药企争夺的只是剩下的利润。”微芯生物总裁、首席科学家鲁先平博士直言不讳地指出,国内药企多以价格竞争谋取非常少的利润。“其实,这其中的利润大部分又被中间商、医院或者其他不透明系统瓜分了,真正留给药企承担风险的能力和正常的
The world’s largest producer of pharmaceutical preparations, the second largest raw material synthesis country and a big generic pharmaceutical producer, are the positions that the pharmaceutical industry in the world has for China. This looks beautiful aura behind, but it is China’s pharmaceutical market at the county level and above three hospitals 60% of the products provided by multinational pharmaceutical companies, 65% of the profits for all multinational embarrassing situation. ”This means that nearly 4,000 domestic pharmaceutical companies compete for only the remaining profits. “ Microbiology president, chief scientist Dr. Lu Xianping bluntly pointed out that the domestic pharmaceutical companies to price competition and make very little profit . ”In fact, most of these profits have been carved up by middlemen, hospitals or other opaque system, the real ability to take the pharmaceutical companies to take risks and normal